oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
The four types of gout are:
- Acute gout
- Intercritical gout and chronic tophaceous gout
The condition can be classified into primary or secondary gout depending on the cause of hyperuricaemia:
- Primary gout occurs mainly in men aged 30-60 years presenting with acute attacks.
- Normally, secondary gout is due to chronic diuretic therapy. It occurs in older subjects, both men and women, and is often associated with osteoarthritis.
It affects both upper and lower limbs with acute attacks. Less often it presents with painful, tophaceous deposits (± discharge) in Heberden's and Bouchard's nodes.
- Most patients with hyperuricaemia never develop gout and gouty patients may not have hyperuricaemia at presentation.
- Patients can be over-excreters of uric acid, normo-excreters or under-excreters.
- Most cases of primary gout are due to undersecretion.
- About 10% are due to overproduction.
- Genome-wide association studies have found that the urate transporter genes SLC2A9, ABCG2 and SLC22A12 modulate serum uric acid (SUA) levels and gout risk.
- Proinflammatory cytokine interleukin-1 (IL-1) has been identified as having a central role in the inflammatory process associated with gout.
- Research using the UK primary care database reported the incidence of gout per 1,000 person-years to be 2.68 (4.42 in men and 1.32 in women) for the years 2000-2007. The prevalence increased with age.
- Asian populations and people of the Pacific Islands have a much higher prevalence and more severe disease.
- The male to female ratio is 9:1. The prevalence increases in women after the menopause although this is partly reduced by hormone replacement therapy.
- Factors such as the introduction of fructose-high corn sweetener and the rise in obesity have led to a dramatic increase in the incidence of gout in developed countries such as America.
The European League Against Rheumatism (EULAR) produced evidence-based guidelines in 2006. It identified the following risk factors:
- Male sex
- Alcohol (10 or more grams per day)
- Coronary heart disease
- Diabetes mellitus
- Chronic renal failure
- High triglycerides
Other factors since identified include chemotherapeutic drugs, psoriasis and heart failure. The presence of previous joint morbidity and trauma may influence which joint is affected.
- The EULAR guidelines for diagnosis suggest that the development of acute pain in a joint which becomes swollen, tender and erythematous and which reaches its crescendo over a 6- to 12-hour period is highly suggestive of crystal arthropathy, though not specifically of gout.
- 50% of all attacks and 70% of first attacks affect the first metatarsophalangeal joint.
- Other sites often affected are:
- Midtarsal joints
- Small hand joints
- The inflammation reaches its peak within 24 hours, often with fever and malaise.
Some patients may only present with connective tissue tophi.
- There is florid synovitis and swelling and extreme tenderness with overlying erythema. Untreated, the attack resolves spontaneously over 5-15 days, usually with itching and desquamation of overlying skin.
- Atypical attacks can occur with tenosynovitis, bursitis and cellulitis, with mild discomfort without swelling lasting a day or two.
- Chronic tophaceous gout - in this condition large crystal deposits produce irregular firm nodules mainly around extensor surfaces of the fingers, hands, forearms, elbows, Achilles tendons and ears.
- Typically, tophi are asymmetrical with a chalky appearance beneath the skin. Damage is usually found in the first metatarsophalangeal joints, mid-foot, small finger joint and wrist, with restricted movement, crepitus and deformity.
- Acute attacks - sepsis and other forms of crystal-related synovitis.
- Chronic tophaceous - rheumatoid arthritis, generalised nodal osteoarthritis, xanthomatosis with arthropathy, multicentric reticulohistiocytosis.
The EULAR guidelines recommend the following evidence-based approach:
- For typical presentations such as inflammation of the first metatarsophalangeal joint (also known as podagra) with hyperuricaemia, a clinical diagnosis can be made with reasonable accuracy but is not definitive unless the presence of uric acid crystals can be demonstrated.
- Demonstration of MSU crystals in synovial fluid or tophi confirms the diagnosis of gout.
- Since gout can present atypically, an opportunity should be taken to examine all samples of synovial fluid aspirated from joints for MSU crystals, even if not inflamed at the time.
- Gram staining and culture of synovial fluid should be arranged, even if MSU crystals are found, since gout and sepsis can co-exist.
- Although a raised SUA level is an important risk factor for gout, the use of SUA as a diagnostic test is limited. It can be normal during acute gout, whilst patients with hyperuricaemia may never develop an attack. Studies suggest that the cut-off point above which a level can be considered raised is 360 μmol/L.
- Renal uric acid secretion (as detected by a 24-hour urine sample) may be helpful in diagnosis, particularly in patients with a family history of young-onset gout, patients whose first attack of gout was under the age of 25 and patients with renal stones. Such patients are likely to be over-excreters of uric acid.
- Radiographs may be useful in chronic gout, when punched-out lesions, areas of sclerosis and, in the latter stages, tophi may be seen. The first lesions usually occur in and around the first metatarsophalangeal joint. CT scanning may be helpful in less accessible areas. Radiography is less helpful in early gout or during an acute attack.
- Fasting glucose and lipids should be performed to rule out hyperglycaemia and hyperlipidaemia, as gout is commonly associated with metabolic syndrome.
An ice pack may be useful, as may rest. The joint should be elevated and trauma avoided.
Pharmacological therapeutic options include:
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Other primarily analgesic compounds
The choice for a particular patient will depend on:
- The gap between onset of symptoms and the start of treatment
- Risks versus benefits
EULAR guidelines recommend colchicine and/or NSAIDs as the first-line option for acute gout.
Canakinumab is a recombinant monoclonal antibody active as an inhibitor of proinflammatory cytokine IL-1. It is licensed for use in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them. It can be used for the symptomatic treatment of frequent gouty arthritis attacks (at least three in the previous 12 months).
Non-steroidal anti-inflammatory drugs
NSAIDs are the first-line treatment. The sooner medication is started, the more rapid the response. Consider giving the patient a stock to keep at home.
Indometacin has been traditionally used first-line in the past but there is no convincing evidence to support the use of any particular NSAID. Eight drugs are licensed for use in gout. Diclofenac, naproxen and indometacin are generally preferred.
For patients with a high risk of gastrointestinal adverse events, use a gastro-protective agent, simple analgesia, or colchicine.
Tailor the dose to the needs of the patient, bearing in mind age, comorbidity and interactions with other drugs. Aim for the highest tolerable licensed dose but be aware of the Commission on Human Medicine's guidance to use NSAIDs for the shortest possible time in view of cardiovascular risk.
Colchicine is an effective treatment for gout. The British National Formulary (BNF) recommends 500 micrograms 2–4 times daily until symptoms are relieved - maximum 6 mg per course; the course is not to be repeated within three days. In practice, the maximum dose is often limited by the development of toxicity symptoms (nausea, vomiting, diarrhoea).
Colchicine is particularly appropriate when NSAIDs are poorly tolerated, in patients with heart failure and in those who are on anticoagulants.
The drug can be effective at lower doses. Titrate up to the maximum licensed dose, according to response.
These can be given orally, intramuscularly, intravenously or intra-articularly. They are useful where NSAIDs or colchicine are contra-indicated.
There are no definitive trials regarding dosage but UK practice is to use short courses of lower doses - 15 mg/day of prednisolone or less. Randomised trials using 30-35 mg of prednisolone reported a low incidence of side-effects. Systemic steroids are widely used although a Cochrane review found limited evidence of effectiveness.
An intramuscular corticosteroid injection can be useful in podagra.
Intra-articular administration of long-acting steroids has been shown, in small trials, to be safe and effective. However, further work is needed to clarify effectiveness. It can be paired with aspiration of the joint, making it convenient to both aid diagnosis and manage the condition. It is particularly useful for those patients with a severe monoarthritis and contra-indications to NSAIDs and colchicine. It is also useful as it is associated with minimal adverse effects and a lower risk of drug interactions. It should not be undertaken if septic arthritis is suspected.
These are useful where all other drug groups are contra-indicated or as an adjunct for pain relief. Start with paracetamol, with or without codeine, taken regularly rather than 'prn'.
If there is no improvement after 2-3 days:
- Review the diagnosis (differentials include septic arthritis, non-urate arthropathy, other arthritides and haemochromatosis).
- Check medicine compliance.
- Increase doses to the maximum.
- If the patient still fails to improve, consider combining treatments, or seek specialist advice.
The central role recently identified for proinflammatory cytokine IL-1 has led to the development of inhibitors such as anakinra, canakinumab and rilonacept. Other advances in genome technology have helped to increase our understanding of urate metabolism and are likely to lead to further therapeutic innovations.
- Renal disease:
- An American study reported that 24% of patients with gout had nephrolithiasis.
- Chronic urate nephropathy results from widespread deposition of urate crystals in the interstitium of medulla and pyramids causing inflammation and fibrosis. Reduced glomerular filtration rate is a recognised complication of gout. It was associated with older age of onset, longer duration of gout and higher levels of maximum SUA.
- Gout patients who have a 24-hour urinary excretion of uric acid above 780 mmol/L have a 50% risk of developing urate and oxalate kidney stones. Those with a measured urate excretion greater than 800 mg per 24 hours may benefit from allopurinol prophylaxis to prevent urate nephropathy.
- Severe degenerative arthritis.
- Secondary infections.
- Recurrent painful episodes.
- Carpal tunnel syndrome (rare).
- Nerve or spinal cord impingement.
Further attacks will usually occur within the first year, if at all.
Prognosis is usually good with early treatment.
Sometimes the attacks become more frequent and involve more sites, eventually causing joint damage and chronic pain (usually after ten10 years).
Observational studies support the link between lifestyle factors and gout, although it is interesting to note that there is a lack of high-quality evidence from randomised controlled trials either to support or refute the use of lifestyle modifications for improving outcomes in chronic gout.
Asymptomatic hyperuricaemia is NOT gout and does not warrant management with drugs. However, evidence suggests that hyperuricaemia may well play a role in the development of neurological and cardiorenal pathology. Further research is required to establish whether normalisation of uric acid levels would result in clinical benefit. Irrespective of pharmacological treatment, patients with asymptomatic hyperuricaemia should be given advice on lifestyle modification:
- Drink alcohol sensibly (eg, keep to recommended limits and have three alcohol-free days a week). Beer or spirits should be avoided (there is a particularly strong link with beer, stout and port wines) but wine in moderation is not associated with an increased risk.
- Avoid dehydration.
- Dietary intervention - reduction of purine-based foods.
- Meat or seafood significantly increase the incidence of gout.
- Highest purine levels are found in heart, herring, sardines and mussels.
- Other foods which are very rich in purines include liver, kidneys, yeast extracts and oatmeal.
- Soya foods are also high in purines but are less likely to lead to gout than meats and seafood.
- It is the quantity of purine-rich food consumed that is more important than the absolute purine content in each food.
- Soft drinks containing high levels of fructose can affect the levels of purines and should also be avoided.
- There is no evidence to support a reduction in purine-rich vegetables such as peas, beans, mushrooms or cauliflower.
- Weight reduction - there is increasing evidence to support a link between obesity and gout.
- Regular exercise is beneficial.
- Smoking cessation should be encouraged,
Manage risk factors
These may include:
- Drugs causing hyperuricaemia:
- Thiazides and loop diuretics.
- Low-dose salicylates - eg, aspirin <1 g/day, pyrazinamide, ethambutol, nicotinic acid, ciclosporin.
- Impaired renal function.
- Hyperlipidaemia, especially hypertriglyceridaemia.[
- Vascular disease.
- Chemotherapy - consider starting prophylaxis before treatment begins.
- Myeloproliferative disease.
NB: aspirin in low doses (75–150 mg/day) has insignificant effects on the plasma urate and should be used as required for cardiovascular prophylaxis.
It is important to explain that medication is normally lifelong and regular monitoring is needed. Advise the person that allopurinol may cause acute attacks of gout just after initiating treatment and for some weeks afterwards. Explain that they should start their anti-inflammatory treatment as soon as possible and not stop their allopurinol during acute attacks.
Manage recurrent attacks of gout by starting allopurinol after two or more attacks within a year.
- Uric acid-lowering drug therapy should also be offered to patients with:
- Renal insufficiency.
- Uric acid stones and gout.
- The need for continuing diuretic treatment.
- Allopurinol should never be started during an acute attack. Wait for 1-2 weeks after the attack resolves.
- Start with a low dose (50-100 mg) and increase in 50-100 mg increments every 2-4 weeks until SUA level is below 300 μmol/L.
- Maximum dose is 900 mg daily.
- The timescale for increasing in dose may need to be slower in some patients, with frequent checks of renal function, if renal function is known to be impaired.
- Co-prescribe colchicine or a low dose non-steroidal anti-inflammatory drug (NSAID) to prevent an attack of gout whilst initiating therapy, and continue until after hyperuricaemia has settled (usually a total of three months).
- If an acute attack develops during treatment, maintain the dose but add colchicine or NSAIDs.
- If neither NSAIDs nor colchicine are tolerated, or both are contra-indicated, consider low dose oral prednisolone. However, it may be preferable to seek specialist advice.
This drug is traditionally the first choice for long-term control of gout. It is not indicated for asymptomatic hyperuricaemia. It is useful where renal function is impaired or renal stones are present.
This is recommended as an option for the management of chronic hyperuricaemia in gout but only in patients where urate deposition has already occurred and not in cases where urate formation has greatly increased such as malignancy. The Medicines and Healthcare products Regulatory Agency (MHRA) issued advice in 2012 that febuxostat can cause serious hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock. The National Institute for Health and Care Excellence (NICE) has issued guidance recommending that febuxostat should be reserved for patients intolerant of allopurinol, (ie adverse effects severe enough to warrant discontinuation, or to prevent full dose escalation for optimal effectiveness).
This can be used as an alternative to allopurinol if toxicity occurs, or as an adjunct in resistant cases. It can be difficult to obtain (a generic form is available) and is contra-indicated in renal failure and urolithiasis.
The dose is 200-800 mg/day in patients with normal renal function.
Although not a urate-lowering drug per se, colchicine is sometimes prescribed at low dose in early gout - to 'buy time' in patients undergoing lifestyle modification, before a commitment to urate-lowering drugs is made.
Low-dose corticosteroids and NSAIDs have also been used to buy time, in the same way as colchicine.
Probenecid is a less powerful uricosuric agent and is relatively contra-indicated in urolithiasis.
Benzbromarone can also be used in patients with mild/moderate renal insufficiency at a dose of 50-200 mg/day. However, it carries a small risk of hepatotoxicity.
Further reading & references
- Martinon F, Glimcher LH; Gout: new insights into an old disease. J Clin Invest. 2006 Aug;116(8):2073-5.
- Zhang W, Doherty M, Pascual E, et al; EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1301-11. Epub 2006 May 17.
- Basseville A, Bates SE; Gout, genetics and ABC transporters. F1000 Biol Rep. 2011;3:23. doi: 10.3410/B3-23. Epub 2011 Nov 1.
- Reginato AM, Mount DB, Yang I, et al; The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012 Oct;8(10):610-21. doi: 10.1038/nrrheum.2012.144. Epub 2012 Sep 4.
- Tran TH, Pham JT, Shafeeq H, et al; Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy. 2013 Jul;33(7):744-53. doi: 10.1002/phar.1265. Epub 2013 Apr 3.
- Cea Soriano L, Rothenbacher D, Choi HK, et al; Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011 Mar 3;13(2):R39. doi: 10.1186/ar3272.
- Hollis-Moffatt JE, Gow PJ, Harrison AA, et al; The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity. Arthritis Res Ther. 2011 Jun 9;13(3):R85. doi: 10.1186/ar3356.
- Wheeless C; Gout, Textbook of Orthopaedics, 2013.
- Hak AE, Curhan GC, Grodstein F, et al; Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010 Jul;69(7):1305-9. doi: 10.1136/ard.2009.109884. Epub 2009 Jul 9.
- Kedar E, Simkin PA; A perspective on diet and gout. Adv Chronic Kidney Dis. 2012 Nov;19(6):392-7. doi: 10.1053/j.ackd.2012.07.011.
- Mirzoyev S, Anavekar N; Gout, have we met before? No, not like this... J Gen Intern Med. 2006 Dec;21(12):C5-7.
- Gout; NICE CKS, August 2012
- Thissen CA, Frank J, Lucker GP; Tophi as first clinical sign of gout. Int J Dermatol. 2008 Nov;47 Suppl 1:49-51. doi: 10.1111/j.1365-4632.2008.03961.x.
- McQueen FM, Reeves Q, Dalbeth N; New insights into an old disease: advanced imaging in the diagnosis and management of gout. Postgrad Med J. 2013 Feb;89(1048):87-93. doi: 10.1136/postgradmedj-2012-131000. Epub 2012 Oct 30.
- Zhang W, Doherty M, Bardin T, et al; EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1312-24. Epub 2006 May 17.
- Moi JH, Sriranganathan MK, Edwards CJ, et al; Lifestyle interventions for chronic gout. Cochrane Database Syst Rev. 2013 May 31;5:CD010039. doi: 10.1002/14651858.CD010039.pub2.
- British National Formulary
- Singh JA; Emerging therapies for gout. Expert Opin Emerg Drugs. 2012 Dec;17(4):511-8. doi: 10.1517/14728214.2012.736488. Epub 2012 Nov 6.
- Burns CM, Wortmann RL; Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis. 2012 Nov;3(6):271-86. doi: 10.1177/2040622312462056.
- Laubscher T, Dumont Z, Regier L, et al; Taking the stress out of managing gout. Can Fam Physician. 2009 Dec;55(12):1209-12.
- Hooper L, Brown TJ, Elliott R, et al; The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004 Oct 23;329(7472):948. Epub 2004 Oct 8.
- NSAIDs and adverse effects; Bandolier, 2007
- Darling EK, McDonald H; A meta-analysis of the efficacy of ocular prophylactic agents used for the J Midwifery Womens Health. 2010 Jul;55(4):319-27.
- Wertheimer AI, Davis MW, Lauterio TJ; A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin. 2011 May;27(5):931-7. doi: 10.1185/03007995.2011.563284. Epub 2011 Mar 3.
- Richette P, Bardin T; Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010 Dec;11(17):2933-8. doi: 10.1517/14656566.2010.529432.
- Rider TG, Jordan KM; The modern management of gout. Rheumatology (Oxford). 2010 Jan;49(1):5-14. doi: 10.1093/rheumatology/kep306. Epub 2009 Oct 5.
- Underwood M; Diagnosis and management of gout. BMJ. 2006 Jun 3;332(7553):1315-19.
- Cochrane Musculoskeletal Group review: Acute Gout; The Journal of Family Practice, 2009
- Sakurai H; Urate transporters in the genomic era. Curr Opin Nephrol Hypertens. 2013 Sep;22(5):545-50. doi: 10.1097/MNH.0b013e328363ffc8.
- Zhu Y, Pandya BJ, Choi HK; Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012 Jul;125(7):679-687.e1. doi: 10.1016/j.amjmed.2011.09.033. Epub 2012 May 23.
- Ichikawa N, Taniguchi A, Urano W, et al; Comorbidities in patients with gout. Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1045-50. doi: 10.1080/15257770.2011.596499.
- An Introduction to Gout, Bandolier, 2007
- Jordan KM, Cameron JS, Snaith M, et al; British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007 Aug;46(8):1372-4. Epub 2007 May 23.
- Neogi T; Asymptomatic hyperuricemia: perhaps not so benign? J Rheumatol. 2008 May;35(5):734-7.
- Choi HK, Curhan G; Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008 Feb 9;336(7639):309-12. Epub 2008 Jan 31.
- Zgaga L, Theodoratou E, Kyle J, et al; The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS One. 2012;7(6):e38123. doi: 10.1371/journal.pone.0038123. Epub 2012 Jun 6.
- Dubchak N, Falasca GF; New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis. 2010;3:145-66. doi: 10.2147/IJNRD.S6048. Epub 2010 Nov 24.
- Reinders MK, Jansen TL; Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging. 2010 Feb 2;5:7-18.
- Gout; DermNet NZ
- Guideline for the management of gout; British Society for Rheumatology (2007)
- Summary of Product Characteristics (SPC) - Zyloric® Tablets (allopurinol); Aspen, electronic Medicines Compendium. Revised February 2012.
- Febuxostat for the management of hyperuricaemia in people with gout; NICE Technology Appraisal Guidance, December 2008
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
Dr Laurence Knott
Dr Laurence Knott
Dr Helen Huins